Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pemigatinib Plus Durvalumab (MEDI4736) in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

NCT06728410 is registered in ClinicalTrials.gov with Mehmet Akce as lead sponsor.

NCT NCT06728410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06728410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pemigatinib Plus Durvalumab (MEDI4736) in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Lead sponsor
Mehmet Akce
Phase
Phase 2
Overall status
Recruiting
Start date
January 27, 2026
Completion date
July 31, 2028
Enrollment
38 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

fgfr2 gene mutation, fgfr2 gene rearrangement, intrahepatic cholangiocarcinoma